What is the appropriate dosing, indications, contraindications, and tapering schedule for Effexor (venlafaxine)?

Effexor (Venlafaxine): Dosing, Indications, Contraindications, and Tapering

Start venlafaxine extended-release at 37.5-75 mg once daily and titrate by 75 mg weekly to a target of 150-225 mg/day for most indications, with gradual tapering by 75 mg weekly when discontinuing to avoid withdrawal symptoms.

FDA-Approved Indications

Venlafaxine is FDA-approved for:

• Major Depressive Disorder (MDD)
• Generalized Anxiety Disorder (GAD)
• Social Anxiety Disorder
• Panic Disorder

Only duloxetine (not venlafaxine) has FDA approval for pediatric anxiety disorders (age ≥7 years) 1.

Dosing Recommendations

Standard Adult Dosing

For Depression and Anxiety Disorders:

• Starting dose: 37.5-75 mg once daily (extended-release formulation) 2, 3
• Titration: Increase by 75 mg weekly as tolerated 2
• Target therapeutic dose: 150-225 mg/day 2
• Maximum dose: 225 mg/day (some studies used up to 375 mg/day for depression) 2, 3

For Neuropathic Pain (off-label):

• Starting dose: 37.5 mg once or twice daily 2
• Titration: Increase by 75 mg each week 2
• Target dose: 150-225 mg/day 2
• Duration of adequate trial: 4-6 weeks 2

The evidence strongly supports that 150 mg/day or higher provides superior efficacy compared to 75 mg alone 4, 5. Research shows venlafaxine flexible dosing between 75-150 mg demonstrates superior efficacy over fixed 75 mg dosing 4.

Special Populations

Hepatic Impairment:

• Reduce total daily dose by 50% in mild to moderate hepatic impairment 3
• May require >50% reduction in cirrhosis due to individual variability 3

Renal Impairment:

• Reduce total daily dose by 25-50% when GFR = 10-70 mL/min 3
• Reduce by 50% in patients on hemodialysis 3

Elderly Patients:

• No specific dose adjustment required based on age alone 3
• Use caution and slower titration when increasing doses 2

Pregnancy - Third Trimester:

• Consider tapering in third trimester due to neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding 3

Formulation Considerations

• Extended-release (XR): Once daily dosing; provides slower absorption with less plasma fluctuation 3
• Immediate-release: Requires twice or thrice-daily dosing due to short 5-hour half-life 1
• Food does not affect bioavailability 3
• Time of administration (AM vs PM) does not affect pharmacokinetics 3

Contraindications

Absolute Contraindications:

• Concomitant use with MAOIs or within 14 days of MAOI discontinuation 1, 3
• Must wait 7 days after stopping venlafaxine before starting an MAOI 3

Relative Contraindications/Cautions:

• Cardiac disease: Cardiac conduction abnormalities and blood pressure increases can occur; prescribe with caution 2
• Seizure disorders: Venlafaxine has been associated with seizures 1
• Patients with brain metastases: Due to seizure risk (note: this applies more to bupropion per 6, but caution warranted)

Adverse Effects

Common Adverse Effects

• Nausea (most common, especially at initiation) 1, 7
• Diaphoresis, dry mouth 1
• Dizziness, headache 1
• Insomnia or somnolence 1
• Decreased appetite, weight loss 1
• Sexual dysfunction 1

Cardiovascular Effects

• Sustained hypertension and increased blood pressure 1
• Increased pulse 1
• Monitor blood pressure and pulse regularly 1

Serious but Uncommon Adverse Effects

• Suicidal thinking/behavior (through age 24 years) 1
• Serotonin syndrome (especially with concomitant serotonergic medications) 1, 7
• Behavioral activation/agitation, hypomania, mania 1
• Seizures 1
• Abnormal bleeding 1
• Overdose fatalities have been reported with venlafaxine 1
• Greater suicide risk compared to other SNRIs 1

Pharmacogenetic Considerations

CYP2D6 poor metabolizers have increased venlafaxine levels and reduced ODV (active metabolite) levels, potentially increasing risk of adverse effects and overdose fatalities 8, 3. However, total exposure (venlafaxine + ODV) is similar, so routine dose adjustment is not required 3.

Discontinuation/Tapering Schedule

Venlafaxine is strongly associated with discontinuation syndrome and must be tapered gradually 2, 3.

Recommended Tapering Protocol

Standard Taper:

• Reduce by 75 mg weekly 3
• Monitor for discontinuation symptoms 3
• If intolerable symptoms occur, resume previous dose and taper more gradually 3

Individualization:

• Some patients may require slower tapering (e.g., 37.5 mg decrements every 1-2 weeks)
• Never abruptly discontinue 3

Discontinuation Symptoms

Common withdrawal symptoms include:

• Dizziness
• Sensory disturbances
• Agitation/anxiety
• Nausea
• Tremor
• Headache

Monitoring Requirements

Baseline and Ongoing:

• Height and weight 1
• Pulse and blood pressure 1
• No specific laboratory tests recommended 1

Special Monitoring:

• Suicidal ideation (especially in patients ≤24 years) 1
• Blood pressure increases (particularly at higher doses) 2

Maintenance Treatment Duration

• First episode MDD: At least 4 months beyond acute response 3
• Recurrent depression: May benefit from prolonged treatment (up to 52 weeks demonstrated effective) 3
• GAD/Social Anxiety/Panic Disorder: Efficacy demonstrated for 6 months; periodically reassess need for continued treatment 3

Drug Interactions

• MAOIs: Contraindicated due to serotonin syndrome risk 1
• CYP450 interactions: Venlafaxine has minimal effect on CYP450 system compared to SSRIs 1
• Other serotonergic drugs: Increased risk of serotonin syndrome 7

Clinical Pearls

• Venlafaxine demonstrates dose-dependent efficacy: Higher doses (≥150 mg/day) are more effective than 75 mg/day 4, 9, 5
• Dual mechanism: Initially serotonergic at lower doses, becomes noradrenergic at higher doses (≥150 mg) 10
• Adequate trial duration: 4-6 weeks at therapeutic dose 2
• Withdrawal is common: Always taper; never stop abruptly 2, 3
• Cardiovascular monitoring essential: Particularly in patients with cardiac disease or at higher doses 2